Tau reduction in the presence of amyloid-β prevents tau pathology and neuronal death in vivo

Several studies have now supported the use of a tau lowering agent as a possible therapy in the treatment of tauopathy disorders, including Alzheimer’s disease. In human Alzheimer’s disease, however, concurrent amyloid-β deposition appears to synergize and accelerate tau pathological changes. Thus f...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Brain
Autors principals: DeVos, Sarah L, Corjuc, Bianca T, Commins, Caitlin, Dujardin, Simon, Bannon, Riley N, Corjuc, Diana, Moore, Benjamin D, Bennett, Rachel E, Jorfi, Mehdi, Gonzales, Jose A, Dooley, Patrick M, Roe, Allyson D, Pitstick, Rose, Irimia, Daniel, Frosch, Matthew P, Carlson, George A, Hyman, Bradley T
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6022692/
https://ncbi.nlm.nih.gov/pubmed/29733334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/brain/awy117
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars